论文部分内容阅读
近１０余年，第３代化疗方案治疗非霍奇金淋巴瘤（ＮＨＬ）是否优于第１代方案一百颇有争议［１］。从１９８８年７月开始，我们采用国际标准的第３代方案Ｐｒｏ－ＭＡＣＥ－ＣｙｔａＢＯＭ治疗了１５例第１代方案治疗后复发或初治即表现为耐药性的中高度恶性ＮＨＬ患者，现总?
In the past 10 years, it is controversial that the third-generation chemotherapy regimen is superior to the first-generation regimen in treating non-Hodgkin’s lymphoma (NHL) [1]. Since July 1988, we have adopted the third-generation protocol of the international standard Pro-MACE-CytaBOM to treat 15 patients with moderate-high-grade NHL who have relapsed or unresisted after first-line treatment. ?